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Human toxocariasis, which has a worldwide
distribution, is caused by infection with the lar-
vae of the dog ascarid worm Toxocara canis. Pup-
pies infected with adult T. canis release in the fe-
ces large numbers of infectious eggs into the en-
vironment. Eggs accidentally ingested by a pa-
tient, yield larvae that penetrate the intestinal wall
and are carried by the circulation to various or-
gans (Glickman and Schantz, 1981). While the
larvae do not undergo any further development
in the patient, the larvae can cause local immu-
nological reactions which are the basis of
toxocariasis. During their somatic migration
through the organs, the larvae shed huge amounts
of immunogenic glycoproteins known as Toxo-
cara excretory-secretory (TES) antigens. The
shedding of prodigious quantities of TES anti-
gens is believed to be a strategy of the larvae to
escape the immune attack of the host (Gems and
Maizels, 1996).
Most human infections with T. canis larvae
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Abstract. The gene encoding the excretory-secretory antigen TES-120 of dog ascarid worm Toxo-
cara canis was cloned into the bacterium Escherichia coli. The specificity of the recombinant TES-
120 antigen produced by the bacterium was investigated. A total of 45 human serum samples from
patients infected with different helminthes and protozoa, including 8 cases of toxocariasis, were tested
against the recombinant antigens in immunoblot assays. The results from the assays revealed that the
recombinant TES-120 antigen reacted with sera from toxocariasis patients only. This highly specific
recombinant TES-120 antigen can potentially be used for the development of an inexpensive serodi-
agnostic assay for human toxocariasis.
are asymptomatic. In instances of heavy infec-
tion, clinical presentations may be seen. The two
main clinical presentations are visceral larva
migrans (VLM) and ocular larva migrans (OLM)
(Shields, 1984; Schantz, 1989). Diagnosis by
identification of the larvae in the tissues is rarely
done. Antibody detection is the more common
means of confirmation of toxocariasis. The most
common serologic test is enzyme-linked immu-
noassay (ELISA), which uses larval stage anti-
gens extracted from embryonated eggs or TES
antigens released by in vitro cultured larvae (de
Savigny et al, 1979; Jaquier et al, 1991). Assays
using such antigens, have drawbacks. First, the
assays may yield false positive results because of
cross-reactivity with other parasitic nematodes.
Second, in vitro culture of T. canis larvae and
harvest of TES antigens are laborious and time
consuming. Hence, there have been attempts to
produce specific recombinant antigens for use in
toxocariasis seroassays (Yamasaki et al, 1998;
2000).
TES-120 glycoproteins of T. canis larvae are
closely related mucins which form the major con-
stituents of the larval surface coat and ES anti-
gens. Four of the genes encoding these glycopro-
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teins, designated Tc-muc-1 to -4, have been cloned
and characterized (Loukas et al, 2000). Among
the genes, Tc-muc-1 has been shown to be abun-
dantly expressed and its encoded product is highly
antigenic (Gem and Maizels, 1996; Tetteh et al,
1999). We postulated that that TES-120 encoded
by Tc-muc-1 would be a suitable candidate as a
highly specific recombinant antigen for use in
toxocariasis seroassays. In our study, we ex-
pressed the mature TES-120 peptide in the bac-
terium Escherichia coli, and evaluated the recom-
binant TES-120 antigen in immunoblot assays.
Molecular cloning and expression of the Tc-
muc-1 gene were carried out using conventional
molecular biology approach. First, an in vitro cul-
ture of T. canis stage 2 larva (L2) was established
using the method described by Maizels et al
(1984). Total RNA was extracted from 200,000
Fig 2–Time point study of protein expression for recom-
binant pTrcHisC carrying the TES-120 gene in.
At zero time point (lane 2) and after an hour of
induction (lane 3), no recombinant protein was
observed. Recombinant protein started to appear
after two hours (lane 4) and continued for the
next two hours (lanes 5 and 6). Time point two
hours was taken as the starting point of gene ex-
pression. Two types of protein markers were
used to estimate recombinant protein size. Lane
1 shows the Precision protein standards and lane
7 shows the Prestained SDS-PAGE standards.
Estimated size of the recombinant protein is 20.1
kDa.
larvae using TRI Reagent (Molecular Research
Center, Inc, USA). Reverse-transcription of RNA
into cDNA was primed using oligo(dT)24 primer,
and proceeded with SuperscriptTM II reverse tran-
scriptase (GibcoBRL®, Life Technologies Inc,
USA). PCR amplification on the resulting cDNA
was carried out using a primer pair (TES-120F
5´-AGCAGCCGCGGTAATT-3´, and TES-120R
5´-AATCTCTAGTCGGCAT-3´), designed ac-
cording to the sequence published by Gems and
Maizels (1996). The TES-120 PCR fragment of
528 base pairs (Fig 1) was ligated into the inter-
mediate plasmid vector pCR®2.1-TOPO
(Invitrogen Corp, USA) and transformed into
competent E. coli TOP10 cells. The TES-120 frag-
ment in the recombinant plasmid was then ex-
cised with EcoRI and spliced ‘in-frame’ into the
EcoRI cloning site of plasmid expression vector
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Fig 1–Agarose gel electrophoresis of TES-120 PCR prod-
ucts after RT-PCR. RT-PCR was performed using
a oligo(dT)24 and TES-120 specific primers. The
amplified DNA fragments were 528 bp (lanes 1-
4) in size. Lane 5 was loaded with the negative
control, in which water was used to replace RNA
in the RT-PCR. Lane 6 is the 1 kb ladder with the
molecular weight (bp) stated beside.
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pTrcHis2C (Invitrogen Corp, USA). Positive re-
combinant clones harboring the TES-120 frag-
ment were verified via nucleotide sequencing
(data not shown).
The expression of the TES-120 antigen in
E. coli was induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) 3 hours after ini-
tiation of culture. Protein was harvested at hourly
intervals from pelleted E. coli cells, and analyzed
in denaturing SDS-polyacrylamide (SDS-PAGE)
gels (Laemmli, 1970) stained with Coomassie
blue. Gel analysis showed the expression of re-
combinant TES-120 antigen, with the expected
size of 20.1 kDa (17.6 kDa of TES-120 polypep-
tide plus 2.5 kDa of tag sequence of the
pTrcHis2C vector), 2 hours after induction (Fig
2). This time interval was used as guide when
growth and expression was done in a larger vol-
ume of culture. The recombinant TES-120 anti-
gen extracted from a large volume culture was
purified using the Xpress SystemTM (Invitrogen
Corp, USA). The purification system involved the
use of a denaturing agent (urea), and a dialysis
step was carried out to remove these agents. SDS-
PAGE analysis on the dialyzed recombinant TES-
120 antigen showed a major single band (Fig 3).
Purified antigen was electroblotted to nitrocellu-
lose membranes and tested with serum samples
of patients suffering helminthic and protozoal
infections.
Eight of the serum samples were from pa-
tients who were clinically and serologically (us-
ing a commercial immunoassay kit) confirmed
as having toxocariasis. Twenty-two samples were
from individuals who were serologically positive
for parasitic infections such as cysticercosis (5
samples), filariasis (5), malaria (2), amebiasis (5)
and toxoplasmosis (5). In addition, sera from in-
dividuals with soil transmitted helminthiasis
(STH) were also tested.  Five serum samples were
from individuals with Ascaris lumbricoides and
Trichuris trichiura co-infection, 3 with T.
trichiura infection, and 1 each from cases of A.
lumbricoides and hookworm infection. In these
STH cases, the individuals were confirmed posi-
tive by the finding of helminth eggs in their fe-
ces. As a control, 5 sera from normal healthy in-
dividuals were included in the immunoblot as-
says. Results from the immunoblot assays showed
Fig 3–Large-scale protein expression and purification
of recombinant TES-120 antigen. E. coli cells
were grown for 3 hours before 1 mM IPTG was
added, and the culture was allowed to grow for
a further 2 hours. The recombinant TES-120
antigen expressed was as the estimated size, 20.1
kDa (lane 2). This protein was purified using
Xpress system and dialyzed (lane 1). Positive
expression control (pTrcHis2/lacZ, provided by
the manufacturer of the expression system)
yields the expected 122.5 kDa β-galactosidase
fusion protein (lane 5). Negative controls such as
cells harboring non-recombinant pTrcHis2C
plasmid and non-induced cells were also loaded
into the gel (lanes 3 and 4, respectively).
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Fig 4–A sample immunoblot assay is shown above. Re-
combinant TES-120 antigen produced in E. coli
was electroblotted onto nitrocellulose membrane
strips. Each strip was tested with a serum sample.
Strips 3, 6 and 12 show bands indicating reaction
between sera from three toxocariasis patients and
the recombinant antigen (20.1 kDa). Other strips
tested with sera from a healthy individual (strip
1) and those infected with other parasites show
no reaction bands. Strip M is the protein size
standards (kDa).
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that the recombinant TES-120 antigen was de-
tected in all the toxocariasis patients’ sera but none
in the normal or non-Toxocara parasitic infection
sera (a sample blot is presented in Fig 4). The
results indicate that the recombinant antigen was
specific for anti-Toxocara antibody. In addition,
the recombinant TES-120 antigen did not cross-
react with antibodies from patients with other
helminthic infections.
Most of the commercial toxocariasis
seroassay kits use total TES antigens derived from
in vitro larva culture. These antigens are hetero-
geneous in their composition, and this may in-
crease the risk of cross-reaction with non-Toxo-
cara helminth antibodies. Using a single or ho-
mogenous species of T. canis larval antigen, such
as those produced by recombinant DNA technol-
ogy, should be more reliable and specific. One of
the main explanations for cross-reactivity among
helminth protein antigens is the occurrence of
common carbohydrate (glycosyl) moieties in their
peptides. Prokaryotic expression systems such as
E. coli produce non-glycosylated proteins, there-
fore, the use of such proteins in seroassays would
reduce the possibility of cross-reactivity. Another
advantage of utilizing E. coli to produce recom-
binant antigens is that the technology for large
scale culture or fermentation of this bacterium is
well established. Furthermore, it is simpler and
less expensive to grow E. coli than any other or-
ganism in vitro, because E. coli is not a fastidious
organism and can be grown in simple and inex-
pensive growth media.
The findings of our study have laid the foun-
dation for our further endeavor in producing a
highly specific recombinant antigen that can be
used for the development of an inexpensive
seroassay kit for human toxocariasis.
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